Is Broadcom Stock Overvalued?
The semiconductor company Broadcom Inc. (NASDAQ:AVGO) is having a stellar…
Sell
29
MRUS Quote, Financials, Valuation and Earnings
Last price:
$43.85
Seasonality move
:
0.36%
Day range:
$41.38 - $47.75
52-week range:
$31.27 - $61.61
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
75.06x
P/B ratio:
4.27x
Volume:
1.8M
Avg. volume:
614.6K
1-year change:
33.36%
Market cap:
$3B
Revenue:
$43.9M
EPS (TTM):
-$3.95
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MRUS
Merus NV
|
$9M | -$0.94 | -4.27% | -10.77% | $86.07 |
|
ARGX
argenx SE
|
$647.7M | $1.11 | 58.02% | -44.75% | $678.84 |
|
PHAR
Pharming Group
|
$80.6M | $0.01 | 0.91% | -62.5% | $27.00 |
|
PRQR
ProQR Therapeutics NV
|
$6.4M | -$0.15 | 25.16% | -79.76% | $9.17 |
|
QGEN
Qiagen NV
|
$519.1M | $0.60 | 1.95% | 39.42% | $51.14 |
|
QURE
uniQure NV
|
$19M | -$0.53 | 194.09% | -62.87% | $30.59 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MRUS
Merus NV
|
$43.85 | $86.07 | $3B | -- | $0.00 | 0% | 75.06x |
|
ARGX
argenx SE
|
$656.26 | $678.84 | $39.2B | -- | $0.00 | 0% | 21.51x |
|
PHAR
Pharming Group
|
$9.71 | $27.00 | $658.7M | -- | $0.00 | 0% | 2.52x |
|
PRQR
ProQR Therapeutics NV
|
$2.42 | $9.17 | $256.3M | -- | $0.00 | 0% | 10.18x |
|
QGEN
Qiagen NV
|
$44.68 | $51.14 | $9.9B | 109.88x | $1.28 | 0% | 4.97x |
|
QURE
uniQure NV
|
$13.85 | $30.59 | $675.1M | -- | $0.00 | 0% | 23.44x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MRUS
Merus NV
|
-- | 1.670 | -- | 7.94x |
|
ARGX
argenx SE
|
-- | 0.387 | -- | 7.52x |
|
PHAR
Pharming Group
|
29.71% | -2.605 | 17.05% | 2.76x |
|
PRQR
ProQR Therapeutics NV
|
15.29% | -0.393 | 3.39% | 2.29x |
|
QGEN
Qiagen NV
|
35.23% | 0.190 | 18.96% | 1.62x |
|
QURE
uniQure NV
|
47.8% | -7.855 | 21.27% | 6.18x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MRUS
Merus NV
|
-- | -$72.2M | -47.97% | -47.97% | -613.59% | -$80.7M |
|
ARGX
argenx SE
|
$514.2M | $16.2M | -5.47% | -6.01% | 15.47% | -$147M |
|
PHAR
Pharming Group
|
$68M | $4.1M | -5.33% | -8.24% | 6.03% | $9.4M |
|
PRQR
ProQR Therapeutics NV
|
-- | -$9.7M | -59.09% | -66.59% | -230.39% | -$7.1M |
|
QGEN
Qiagen NV
|
$308.3M | $120.8M | 1.8% | 2.58% | 25.49% | $138M |
|
QURE
uniQure NV
|
$1.3M | -$40.2M | -96.96% | -154.29% | -1215.48% | -$45.3M |
Merus NV vs. Competitors
-
Which has Higher Returns MRUS or ARGX?
argenx SE has a net margin of -848.67% compared to Merus NV's net margin of 15.95%. Merus NV's return on equity of -47.97% beat argenx SE's return on equity of -6.01%.
Company Gross Margin Earnings Per Share Invested Capital MRUSMerus NV-- -$1.46 $703.3M ARGXargenx SE89.7% $1.39 $4.3B -
What do Analysts Say About MRUS or ARGX?
Merus NV has a consensus price target of $86.07, signalling upside risk potential of 96.29%. On the other hand argenx SE has an analysts' consensus of $678.84 which suggests that it could grow by 3.44%. Given that Merus NV has higher upside potential than argenx SE, analysts believe Merus NV is more attractive than argenx SE.
Company Buy Ratings Hold Ratings Sell Ratings MRUSMerus NV12 0 0 ARGXargenx SE13 2 0 -
Is MRUS or ARGX More Risky?
Merus NV has a beta of 1.104, which suggesting that the stock is 10.426% more volatile than S&P 500. In comparison argenx SE has a beta of 0.587, suggesting its less volatile than the S&P 500 by 41.304%.
-
Which is a Better Dividend Stock MRUS or ARGX?
Merus NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. argenx SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merus NV pays -- of its earnings as a dividend. argenx SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRUS or ARGX?
Merus NV quarterly revenues are $11.8M, which are smaller than argenx SE quarterly revenues of $573.2M. Merus NV's net income of -$99.9M is lower than argenx SE's net income of $91.4M. Notably, Merus NV's price-to-earnings ratio is -- while argenx SE's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merus NV is 75.06x versus 21.51x for argenx SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRUSMerus NV75.06x -- $11.8M -$99.9M ARGXargenx SE21.51x -- $573.2M $91.4M
-
Which has Higher Returns MRUS or PHAR?
Pharming Group has a net margin of -848.67% compared to Merus NV's net margin of -1.38%. Merus NV's return on equity of -47.97% beat Pharming Group's return on equity of -8.24%.
Company Gross Margin Earnings Per Share Invested Capital MRUSMerus NV-- -$1.46 $703.3M PHARPharming Group90.89% -$0.02 $321.2M -
What do Analysts Say About MRUS or PHAR?
Merus NV has a consensus price target of $86.07, signalling upside risk potential of 96.29%. On the other hand Pharming Group has an analysts' consensus of $27.00 which suggests that it could grow by 178.06%. Given that Pharming Group has higher upside potential than Merus NV, analysts believe Pharming Group is more attractive than Merus NV.
Company Buy Ratings Hold Ratings Sell Ratings MRUSMerus NV12 0 0 PHARPharming Group2 0 0 -
Is MRUS or PHAR More Risky?
Merus NV has a beta of 1.104, which suggesting that the stock is 10.426% more volatile than S&P 500. In comparison Pharming Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MRUS or PHAR?
Merus NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharming Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merus NV pays -- of its earnings as a dividend. Pharming Group pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRUS or PHAR?
Merus NV quarterly revenues are $11.8M, which are smaller than Pharming Group quarterly revenues of $74.8M. Merus NV's net income of -$99.9M is lower than Pharming Group's net income of -$1M. Notably, Merus NV's price-to-earnings ratio is -- while Pharming Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merus NV is 75.06x versus 2.52x for Pharming Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRUSMerus NV75.06x -- $11.8M -$99.9M PHARPharming Group2.52x -- $74.8M -$1M
-
Which has Higher Returns MRUS or PRQR?
ProQR Therapeutics NV has a net margin of -848.67% compared to Merus NV's net margin of -210.98%. Merus NV's return on equity of -47.97% beat ProQR Therapeutics NV's return on equity of -66.59%.
Company Gross Margin Earnings Per Share Invested Capital MRUSMerus NV-- -$1.46 $703.3M PRQRProQR Therapeutics NV-- -$0.11 $32.9M -
What do Analysts Say About MRUS or PRQR?
Merus NV has a consensus price target of $86.07, signalling upside risk potential of 96.29%. On the other hand ProQR Therapeutics NV has an analysts' consensus of $9.17 which suggests that it could grow by 230.58%. Given that ProQR Therapeutics NV has higher upside potential than Merus NV, analysts believe ProQR Therapeutics NV is more attractive than Merus NV.
Company Buy Ratings Hold Ratings Sell Ratings MRUSMerus NV12 0 0 PRQRProQR Therapeutics NV4 1 0 -
Is MRUS or PRQR More Risky?
Merus NV has a beta of 1.104, which suggesting that the stock is 10.426% more volatile than S&P 500. In comparison ProQR Therapeutics NV has a beta of 0.303, suggesting its less volatile than the S&P 500 by 69.727%.
-
Which is a Better Dividend Stock MRUS or PRQR?
Merus NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProQR Therapeutics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merus NV pays -- of its earnings as a dividend. ProQR Therapeutics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRUS or PRQR?
Merus NV quarterly revenues are $11.8M, which are larger than ProQR Therapeutics NV quarterly revenues of $4.2M. Merus NV's net income of -$99.9M is lower than ProQR Therapeutics NV's net income of -$8.9M. Notably, Merus NV's price-to-earnings ratio is -- while ProQR Therapeutics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merus NV is 75.06x versus 10.18x for ProQR Therapeutics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRUSMerus NV75.06x -- $11.8M -$99.9M PRQRProQR Therapeutics NV10.18x -- $4.2M -$8.9M
-
Which has Higher Returns MRUS or QGEN?
Qiagen NV has a net margin of -848.67% compared to Merus NV's net margin of 19.54%. Merus NV's return on equity of -47.97% beat Qiagen NV's return on equity of 2.58%.
Company Gross Margin Earnings Per Share Invested Capital MRUSMerus NV-- -$1.46 $703.3M QGENQiagen NV61.43% $0.44 $5.4B -
What do Analysts Say About MRUS or QGEN?
Merus NV has a consensus price target of $86.07, signalling upside risk potential of 96.29%. On the other hand Qiagen NV has an analysts' consensus of $51.14 which suggests that it could grow by 14.47%. Given that Merus NV has higher upside potential than Qiagen NV, analysts believe Merus NV is more attractive than Qiagen NV.
Company Buy Ratings Hold Ratings Sell Ratings MRUSMerus NV12 0 0 QGENQiagen NV7 7 0 -
Is MRUS or QGEN More Risky?
Merus NV has a beta of 1.104, which suggesting that the stock is 10.426% more volatile than S&P 500. In comparison Qiagen NV has a beta of 0.366, suggesting its less volatile than the S&P 500 by 63.358%.
-
Which is a Better Dividend Stock MRUS or QGEN?
Merus NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Qiagen NV offers a yield of 0% to investors and pays a quarterly dividend of $1.28 per share. Merus NV pays -- of its earnings as a dividend. Qiagen NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRUS or QGEN?
Merus NV quarterly revenues are $11.8M, which are smaller than Qiagen NV quarterly revenues of $501.9M. Merus NV's net income of -$99.9M is lower than Qiagen NV's net income of $98.1M. Notably, Merus NV's price-to-earnings ratio is -- while Qiagen NV's PE ratio is 109.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merus NV is 75.06x versus 4.97x for Qiagen NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRUSMerus NV75.06x -- $11.8M -$99.9M QGENQiagen NV4.97x 109.88x $501.9M $98.1M
-
Which has Higher Returns MRUS or QURE?
uniQure NV has a net margin of -848.67% compared to Merus NV's net margin of -1940.45%. Merus NV's return on equity of -47.97% beat uniQure NV's return on equity of -154.29%.
Company Gross Margin Earnings Per Share Invested Capital MRUSMerus NV-- -$1.46 $703.3M QUREuniQure NV55.36% -$0.91 $106.9M -
What do Analysts Say About MRUS or QURE?
Merus NV has a consensus price target of $86.07, signalling upside risk potential of 96.29%. On the other hand uniQure NV has an analysts' consensus of $30.59 which suggests that it could grow by 120.83%. Given that uniQure NV has higher upside potential than Merus NV, analysts believe uniQure NV is more attractive than Merus NV.
Company Buy Ratings Hold Ratings Sell Ratings MRUSMerus NV12 0 0 QUREuniQure NV8 2 0 -
Is MRUS or QURE More Risky?
Merus NV has a beta of 1.104, which suggesting that the stock is 10.426% more volatile than S&P 500. In comparison uniQure NV has a beta of 0.412, suggesting its less volatile than the S&P 500 by 58.797%.
-
Which is a Better Dividend Stock MRUS or QURE?
Merus NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. uniQure NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merus NV pays -- of its earnings as a dividend. uniQure NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRUS or QURE?
Merus NV quarterly revenues are $11.8M, which are larger than uniQure NV quarterly revenues of $2.3M. Merus NV's net income of -$99.9M is lower than uniQure NV's net income of -$44.4M. Notably, Merus NV's price-to-earnings ratio is -- while uniQure NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merus NV is 75.06x versus 23.44x for uniQure NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRUSMerus NV75.06x -- $11.8M -$99.9M QUREuniQure NV23.44x -- $2.3M -$44.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
4 Top Dividend Stocks to Buy Now
If you’re looking for steady income, dividend stocks are a…
Will Uber Stock Recover?
Shares of Uber Technologies (NYSE:UBER) have had a rough few…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 39x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 114x
Sell
39
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
87
CEG alert for Jan 11
Constellation Energy [CEG] is up 25.15% over the past day.
Sell
1
MCY alert for Jan 11
Mercury General [MCY] is down 19.87% over the past day.
Buy
84
ATZAF alert for Jan 11
Aritzia [ATZAF] is up 17.63% over the past day.
